J.P. Morgan sees mid-cap defense firms like Kratos rebounding in the second half of 2025 amid Pentagon-driven tailwinds.

Wells Fargo analyst Mohit Bansal maintained a Hold rating on Pfizer (PFE – Research Report) yesterday and set a price target of $28.00. The company’s shares closed yesterday a ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ...

Regeneron Pharmaceuticals just got a haircut from Wall Street, with JPMorgan Chase & Co. lowering its price target from $950 ...

Regeneron Pharmaceuticals saw a downgrade from Wells Fargo, slicing its stock rating from "overweight" to "equal weight" and ...

Dollar General might raise prices because of tariffs but it's the last resort, CEO Todd Vasos told investors on an earnings call. The chain is attracting even more lower-income shoppers than usual, ...

Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while maintaining an Overweight rating on the stock. The revision follows what the ...

BMO Capital lowered the firm’s price target on Regeneron (REGN) to $600 from $800 and keeps an Outperform rating on the shares.The firm is updating its model following “disappointing ...

Similar price hikes have been noted at Target as well. For example, a Jurassic World T. Rex toy at Walmart saw its price increase from $39.92 in late April to $55 in late May, a nearly 38% increase.

On Monday, Bernstein SocGen Group lowered the price target for Regeneron Pharma stock (NASDAQ: NASDAQ:REGN) to $750 from $896, while maintaining an Outperform rating. This adjustment follows Regeneron ...